Determining of adding SOVODAK (sofosbuvir + daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study
Design
A clinical trial study will have a control group with a parallel design
Settings and conduct
This study will be performed in Miandrood Medical Clinic. One group of single-drug therapies included hydroxychloroquine tablets (200 mg twice daily for 7 days), the other group of two-drug therapies included a combination of hydroxychloroquine (200 mg twice daily for 7 days) and sudak tablets (60/400 mg). Grams once a day) will receive. Treatment will be with azithromycin capsules (500 mg for 6 days) with naproxen tablets (500 mg, 2 times a day for 7 days) and pantoprazole tablets 40 mg for both groups. Patients in both groups will be given training such as adequate rest, quarantine principles, and breathing capacity training.
Participants/Inclusion and exclusion criteria
Inclusion Criteria: Patients with Quaid 19 confirmed by CT scan findings
Exclusion criteria: َAmiodarone use and patients with specific underlying diseases such as renal failure
Intervention groups
The intervention group will receive hydroxychloroquine + SOVODAK and the comparison group will receive hydroxychloroquine.
The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study
Public title
The effect of SOVODAK in the treatment of COVID-19 patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Diagnosis by CT scan with clinical symptoms
Consent to attend the study
Lymphocyte count less than 1100
Positive CRP test
Exclusion criteria:
History of kidney failure
Pregnancy
Amiodarone consumer
Age
No age limit
Gender
Both
Phase
3
Groups that have been masked
No information
Sample size
Target sample size:
60
Randomization (investigator's opinion)
Randomized
Randomization description
Patients will be divided into two groups by Block Randomization. The block size is 4 people and a random list will be created by the sealedenvelope site. To hide the drugs, they are placed in the required number in the envelope. Then, according to the random codes created, one or two envelopes will be placed in a larger envelope
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Mazandaran University of Medical Sciences